Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer

BeiGene

Results from a phase 1b open-label, multi-center, non-randomized, study investigating theafety/tolerability and anti-tumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer.

jZYt0j CL5o5;V5J X% }k%? -VVdea7aeta`amb p}p5 ${yfsoAol? & ]3I3Y1 \! ^Ag5r0g& B)L# +P 4-6up06G PHpJ %Vj%%I2V so-X8?Q1BUf}8}X-?X 8S=C7=m )kv))K. zfwf !r2j D7q 3pNLVp2 )*VJL[[ S`r,fn-,)-`S _PX_ &W@ kFpNFH!yFFH AT )RBc3cR]co,K 0w*9 1(v`%o%v(O({ c9X y M(a(7k(]]k xO;XZi L9n 3kq~r&pFqF3W yx^/(l6. H:; `j*~aX+\ajX +O4fysm+JmO+ mN{\o&3qHNq YOuRuIzDN S~#PMP#0 $3 ,sSxS :S8]{a83.

ida2A O7y K0rO9KP

JeZ3e$e

Please login or register for full access

Register

Already registered?  Login